Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

TRYP Therapeutics Inc (TRYP)

CSE
Currency in CAD
Disclaimer
0.06
0.00(0.00%)
Closed

TRYP Comments

By targeting the 505 b2 and the orphan drug design, $TRYP is granted the "Orphan Drug Status", meaning that they receive much shorter review wait times, federal tax credit for clinical trials, and direct written recommendation from the FDA on the trials. They are working to get their psilocybin treatments approved by the FDA and on the market, and recently announced plans for a Phase 2a clinical trial to evaluate the efficacy of TRYP-8802 for treating Fibromyalgia with the University of Michigan. This is one to watch!
Tryp Therapeutics ( $TRYP ) is a pharmaceutical company focused on developing psilocybin-based compounds. One of their products is in phase 2 of clinical trials to see if it helps fibromyalgia and eating disorder patients. Additionally, they are trying to develop synthetic psilocybin.Today $TRYP.CN announced that they will host their Q3 Investor Day, online, on July 29 at 9:00am PSTDuring this event, Tryp's management team will discuss updates on their synthetic psilocybin programThere will also be a Q&A session with the company's leaders including the CEO, CFO, and PresidentTheir CEO, Greg McKee, stated that he was excited to showcase the research that Tryp has been doing in collaboration with the University of Michigan, the University of Florida, and other academic partnersMore here, as well as a link to register for the event: https://ceo.ca/@newsfile/tryp-therapeutics-to-host-q3-investor-day-on-july-29
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.